Optimal treatment for Siewert type II and III adenocarcinoma of the esophagogastric junction: A retrospective cohort study with long-term follow-up

Table 2 Pathological characteristics of patients (n = 83) n (%)

	Type II(n = 62)	Type III(n = 21)	P value
T category			0.06
T1b	11 (18)	0 (0)
T2	11 (18)	2 (10)
T3	40 (64)	19 (90)
N category			0.41
N0	21 (34)	4 (19)
N1	12 (19)	6 (29)
N2	13 (21)	3 (14)
N3	14 (23)	6 (29)
LNR	0.063 (0-1)	0.047 (0-0.41)	0.74
M category			0.64
M0	58 (94)	19 (90)
M1	4 (6)	2 (10)
TNM stage			0.30
IA	10 (16)	0 (0)
IB	5 (8)	0 (0)
IIA	6 (10)	4 (19)
IIB	5 (8)	1 (5)
IIIA	8 (13)	5 (24)
IIIB	11 (18)	3 (14)
IIIC	12 (19)	6 (29)
IV	5 (8)	2 (10)
ly category			0.35
ly0	8 (13)	0 (0)
ly1	16 (26)	5 (24)
ly2	22 (35)	9 (43)
ly3	16 (26)	7 (33)
v category			0.55
v0	7 (11)	3 (14)
v1	13 (21)	4 (19)
v2	24 (39)	5 (24)
v3	18 (29)	9 (43)
Histopathological grade			0.56
G1 + G2	37 (60)	11 (52)
G3 + G4	25 (40)	10 (48)

Type II: Siewert type II adenocarcinoma of the esophagogastric junction; Type III: Siewert type III adenocarcinoma of the esophagogastric junction; LNR: Lymph node ratio; ly: Lymphatic invasion; v: Venous invasion.